Cerus (CERS) Scheduled to Post Earnings on Wednesday

Cerus (NASDAQ:CERS) is scheduled to announce its earnings results after the market closes on Wednesday, October 30th. Analysts expect the company to announce earnings of ($0.03) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Cerus (NASDAQ:CERS) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.01. Cerus had a negative return on equity of 44.27% and a negative net margin of 14.15%. The company had revenue of $45.08 million during the quarter, compared to analyst estimates of $42.50 million. During the same quarter last year, the business posted ($0.07) earnings per share. On average, analysts expect Cerus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cerus Trading Up 3.0 %

Shares of CERS stock opened at $1.72 on Tuesday. The company has a market cap of $318.01 million, a PE ratio of -10.12 and a beta of 1.18. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.51 and a quick ratio of 1.83. The stock’s 50 day simple moving average is $1.92 and its two-hundred day simple moving average is $1.92. Cerus has a 1 year low of $1.25 and a 1 year high of $2.59.

Wall Street Analysts Forecast Growth

Separately, Stifel Nicolaus lowered their price target on Cerus from $6.00 to $3.00 and set a “buy” rating for the company in a research report on Thursday, October 17th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $3.63.

Insider Buying and Selling at Cerus

In related news, CFO Kevin Dennis Green sold 28,385 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $2.18, for a total transaction of $61,879.30. Following the completion of the sale, the chief financial officer now directly owns 590,365 shares of the company’s stock, valued at approximately $1,286,995.70. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Richard J. Benjamin sold 21,605 shares of the company’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $2.50, for a total value of $54,012.50. Following the transaction, the insider now directly owns 438,007 shares in the company, valued at approximately $1,095,017.50. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Kevin Dennis Green sold 28,385 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $2.18, for a total transaction of $61,879.30. Following the completion of the transaction, the chief financial officer now directly owns 590,365 shares in the company, valued at $1,286,995.70. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 3.40% of the company’s stock.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.